Podcast appearances and mentions of Gene editing

Sen Lee of Utah took exception with the Pentagon's labelling. NYT announces a new era of gene editing. John talks to Professor Robbie George about Fidelity Month. HelloFresh promotes perversion, A YouTuber is criticized for aborting a preborn baby diagnosed with Down Syndrome, but Bethany Christian Services makes a welcome change.     Segment 1 – Are Mormons Christian? Gene Editing is Back  Breakpoint article  NY Times article on gene editing  Andrew Walker article  Segment 2 – Fidelity Month  Fidelity Month website  Segment 3 – YouTuber Kills Preborn Baby after Down Syndrome Diagnosis  YouTuber article  Spectator Hello Fresh article  Bethany Christian Services statement  Resolve Conflict and Find Peace and Hope with Adult Children: Strategies and Conversations That Work by Kathy Koch       

Peter Singer critiques the Pope on Human Dignity: Scott and Erik discuss philosopher Peter Singer's reaction to the Pope's recent encyclical, analyzing how a purely functional definition of human value leads to terrifying ethical conclusions. The Neurobiology of Fatherhood: Discussing a recent New York Times piece, Scott and Erik break down the scientific evidence showing how active fatherhood positively rewires and protects a man's brain as he ages. Gene Editing and the Genetic Caste System: Analyzing a recent article on "base editing" technologies, the hosts explore the bioethical boundaries between curing diseases and pursuing human enhancements that threaten to create a permanent disparity between medical haves and have-nots.Gen Z Men Resisting Temptation: Highlighting an encouraging cultural trend reported in an article, the hosts discuss how young Gen Z men are actively navigating and resisting the omnipresent temptation to sexual sin enabled by modern technology through the power of community and fellowship. Audience Question: Is it Acceptable to Listen to AI-Generated Worship Music? A listener asks if it is morally or spiritually compromising to listen to classic, human-written hymns that are fully performed by AI voices and instruments. Applying Biblical Accountability (1 Corinthians 5) at Home: The hosts offer nuanced advice to a listener navigating how to handle the apostle Paul's strict instructions regarding unrepentant believers when that person is an immediate family member living under the same roof. What Alternative Careers Would the Hosts Choose? In a light-hearted closing segment, ethicist Scott Rae and theologian Erik Thoennes share what completely different career paths they might have pursued—such as athletics or screen printing—if they hadn't entered academia and ministry.==========Think Biblically: Conversations on Faith and Culture is a podcast from Talbot School of Theology at Biola University, which offers degrees both online and on campus in Southern California.   Find all episodes of Think Biblically at: https://www.biola.edu/think-biblically.   To submit comments, ask questions, or make suggestions on issues you'd like us to cover or guests you'd like us to have on the podcast, email us at thinkbiblically@biola.edu.  

One of the most surprising and remarkable discoveries in recent scientific history has been CRISPR. Short for Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR is a form of immune system that evolved in bacteria more than a billion years ago to defend against persistent viral threats. Under attack, bacteria can snip a small fragment of a virus's DNA, store it in the CRISPR region of their genome, and then use it to recognize and destroy the same virus if it returns. The CRISPR-Cas9 system, to give it its longer name, consists of a short strand of guide RNA that identifies where to cut the DNA and a protein that acts as the molecular scissors. What made this system truly revolutionary was the demonstration in 2012 that it could be reprogrammed with different pieces of guide RNA to edit virtually any genome in any species, and at a level of precision and ease that far surpassed existing gene-editing tools. Since then, the editing capability of CRISPR has been tested on everything from developing disease treatments to engineering drought-resistant crops to resurrecting genes of extinct species. The possibilities have expanded so rapidly that researchers, ethicists, and regulators have found themselves struggling to keep up. One person acutely aware of the power of CRISPR is Jennifer Doudna, co-developer of the technology. Doudna, who received the Nobel Prize in Chemistry in 2020 with Emmanuelle Charpentier for this pioneering work, has been a prominent voice not only for its vast potential but also for its responsible and ethical use. In this episode of The Joy of Why, Doudna tells co-host Janna Levin how her early, “rebellious,” decision to study RNA led her on a serendipitous path to one of biology's most transformative discoveries. They also discuss the breakthroughs, barriers, and frontiers that will define CRISPR's true impact.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Topics discussed on today's show: National Call Your Doctor Day, Animal News, Mr Potato Head Record, Lab Rats, Gene Editing, Chicken Yeast, Siri, Flying Cars, Masturbating Birds, Science News: Cosmic Wind, Sea Squirts, Leaf, Bird Call, Pop History Quiz, Probably White, Gay Bars and Fart Jars, Vacations, Adam Carolla stops by the show, and Apologies.

We love to hear from our listeners. Send us a message.In episode 2 of this four-part in vivo-focused special series of Cell & Gene: The Podcast, Host Erin Harris sits down with Gopi Shanker, Ph.D., Chief Scientific Officer at Beam Therapeutics, for an in-depth conversation on the rapidly evolving landscape of in vivo gene editing and precision genetic medicines. Dr. Shanker discusses how next-generation base editing technologies are advancing beyond traditional CRISPR approaches by enabling precise single-base changes without creating double-stranded DNA breaks. They discuss the growing momentum behind in vivo delivery strategies, including targeted LNP technologies designed to reach tissues beyond the liver, as well as the operational and patient-centric advantages these approaches may offer compared to ex vivo therapies. Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Technological breakthroughs in recent years with artificial intelligence and gene editing are opening up new possibilities for plant breeders.

We put some cinder blocks under the head of our bed (for science!) before this great episode. A weird study just came out finding that head-up sleeping may increase red blood cell totals. We talk about what it means and what it doesn't mean. Excuse us while we launch a cinderblock start-up.We also discussed a breakthrough in gene editing for cholesterol, and what that could mean for the future. The world is going to be so different in 50 years! Maybe by then, David can use CRISPR to be able to pronounce science words. And this one was full of fun topics! Other topics: our training log discussions, iron levels in athletes, breaking news on heat training from Unbound 200, a science debate on fatigue resistance terminology, and a study on glucose v. fructose. Plus, we answer questions on heat training in the car, clean sport for age group athletes, marathon v. ultra training, and health uncertainty.You're going to learn a lot about what Megan would do for 40 grams of carbs. Totally normal stuff if you ask her!We love you all! HUZZAH!-David and MeganClick "Get 40% Off" button for 40% off at The Feed here: thefeed.com/swapBuy Janji's amazing gear: https://janji.com (code "SWAP")20% flash deal for the Wahoo Kickr Run treadmill on Wednesday: https://www.wahoofitness.com/devices/running/treadmills/kickr-run-buy (code “SWAP”)For training plans, weekly bonus podcasts, heart rate zones, articles, and videos: patreon.com/swap

Can today's technology really prevent tomorrow's diseases? Today, we're talking to Eriona Hysolli, biologist and co-founder of Manhattan Genomics. We discuss why preventing genetic disease before birth is a more powerful idea than treating it in adulthood, how the UK quietly pioneered a procedure that most of the world still considers off-limits, why the loudest opposition to gene editing often comes from bioethicists rather than the public, and what it would actually take to engineer traits — from woolly mouse hair to human limb regeneration — with enough certainty to act on. To learn more about Eriona, connect with her on LinkedIn.

May 29, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Noom launches at-home biomarker kits measuring 17 markers with microneedle collection, finding 70% of users have high LDL cholesterol despite appearing healthy Scientists report single gene-editing infusion lowering LDL cholesterol by 62% with results maintained 18+ months, potentially replacing years of daily medication Retro Biosciences reaches $1.8B valuation backed by Sam Altman, entering human trials testing cellular cleanup process to combat neurodegeneration and age-related disease More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

We love to hear from our listeners. Send us a message.This is Episode 1 of a four-episode in vivo-focused special series of Cell & Gene: The Podcast. Host Erin Harris speaks with Cassie Gorsuch, Ph.D., CSO at Precision Biosciences, about the rapid evolution of in vivo gene editing and the scientific, translational, and regulatory hurdles shaping the field. Dr. Gorsuch discusses how Precision Biosciences approaches in vivo therapeutic development through its Arcus platform, with programs targeting chronic hepatitis B and Duchenne muscular dystrophy. They cover the broader challenges facing in vivo gene editing, including delivery limitations outside the liver, balancing specificity and efficiency, mitigating off-target risks, and translating promising preclinical in vivo data into clinical success.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the U.S. FDA's recent approval of Gilead Sciences' Hepcludex (bulevirtide) for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA-approved therapy targeting chronic hepatitis D virus infection—a niche condition with limited treatment options. Similarly, Pfizer's Braftovi (encorafenib) is expanding its global reach beyond U.S. borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost-cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus Holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is Niowave's $75 million investment in a radiopharmaceutical isotope plant in Michigan, set to produce actinium-225 by 2028—an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the FDA despite leadership changes. Initiatives like the Commissioner's National Priority Voucher program illustrate regulatory bodies' commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine Skyvaricella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R&D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limmatech Biologics, and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases—a field that has gained focus post-COVID-19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a Phase 2 trial of a lipid-lowering gene editor from Verve Therapeutics, showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics—an exciting breakthrough suggesting substantial potential for gene-editing technologies addressing genetic disorders like high cholesterol. In oncology, AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple-negative breast cancer as a first-line treatment. This antibody-drug conjugate targets Trop2, demonstrating the potential of targeted therapy in difficult-to-treat cancers. Kura Oncology's combination therapy featuring darlifarnib and Krazati showed up to a 69% response rate in KRAS G12C-mutated solid tumors during Phase 1 trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase 3 success with bariatric surgery-like outcomes. The drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity—a condition linked with numerous comorbidities. Moderna's mFlusiva is poised for an FDA advisory committee review as an influenza preventative for older adults—an extension of Moderna's mRNA technology initially used against COVID-19. Collectively, these developments highlight an industry leveraging cutting-edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio—a move aligned with global immunization strategies. This follows hiring Peter Marks from the FDA, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by IDEA Pharma as a leader in pharmaceutical innovation—a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies. Across oncology landscapes highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and Akeso's potential Keytruda rivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles—the current environment promises significant advancements offering new hope while demanding strategic agility within healthcare sectors globally.Support the show

Topics discussed on today's show: Memorial Day Weekend, Cause of Death for Kyle Busch, Heidi's AC, Music News, Space X Rocket, Gene Editing for Heart Disease, Death, Electric Ferrari, Growing Fruits and Veggies, AI Open Rolls, Encounters with Nature, Fry Spit, Old Age and Health, Millennial Retirement Gap Year, AI Doctors and Juries, AI or..., New Shopping Cart, Special Guest Grant, Pop History Quiz, and Apologies.

The ongoing outbreak of hantavirus infections that originated with passengers on the Dutch cruise ship MV Hondius in April has generated concerns across the globe. This very rare occurrence has led to a number of deaths, required quarantining of passengers and prompted emergency responses from public health authorities in multiple countries.  On this episode of Raise the Line from Elsevier, we're tapping the expertise of a leading authority on the subject, Dr. Jamie Childs of Yale University, to provide you with a scientific understanding of hantaviruses and what level of threat is posed by this situation. In short, Dr. Childs believes this is not the start of a pandemic. “The Andes variant involved here is one of the most dangerous hantaviruses, but it is totally controllable with contact tracing.” This timely conversation with host Lindsey Smith is informed by Dr. Childs' decades of hantavirus research as well as learnings from his role leading the CDC's environmental investigation during the landmark 1993 hantavirus outbreak in the Four Corners region of the American Southwest. And be sure to stay tuned to hear his concerns about the factors complicating containment of the current Ebola outbreak in East Africa. Note: this conversation was recorded on May 19th, 2026. Mentioned in this episode: Yale School of Public Health Yale Institute for Global Health If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We mark National Mental Health Awareness Month on this episode by tapping the expertise of Dr. Steve Strakowski, an internationally recognized expert in bipolar disorder, who has spent decades studying the neurobiology and treatment of mood conditions while pushing just as hard on the structural barriers that keep effective treatments out of reach for more than half the people who need them. In this conversation with Raise the Line from Elsevier host Michael Carrese, Dr. Strakowski explains why access, not science, is now the biggest obstacle to improving mental health outcomes. He also addresses the heavy toll society pays for underfunding mental health prevention and treatment programs. “The money is spent eventually, but in the most expensive places like emergency rooms and prisons, and there is the human cost of suffering and suicides." This important discussion also covers: The persistent problem of Black patients presenting with mania being misdiagnosed with schizophrenia;  Why he describes bipolar disorder as a reward-processing illness;  The emerging therapies he finds encouraging. Mentioned in this episode:Indiana University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of Genetics in Your World, GSA Early Career Scientists Multimedia Subcommittee member Luke Arnce interviews Caitlin Peaslee of the Center for Embryonic Cell and Gene Therapy at Oregon Health and Science University about her research. Read her paper titled, "Mapping whole-organism genetic comorbidities across model species using unified ontologies," published in the April 2026 issue of GENETICS: https://doi.org/10.1093/genetics/iyag038 This study developed a cross-species computational framework, CoMo DBM, to analyze 204 mouse genes that caused non-obstructive azoospermia and mapped their phenotype associations across human, zebrafish, fruit fly, and roundworm databases. Music: Loopster Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 License, http://creativecommons.org/licenses/by/3.0/#GeneEditing #cancer #GeneOntology Hosted on Acast. See acast.com/privacy for more information.

"When the workforce does not align with the population, your system is misaligned by design." That candid observation comes from Tina Loarte-Rodríguez, DP, RN who has spent much of her two decade career in patient safety, risk management, and systems leadership as the only Latina in the room, which she sees as a signal of a systemic failure that demands structural solutions. As we mark National Nurses Month, Dr. Loarte-Rodríguez joins Raise the Line from Elsevier  host Lindsey Smith to explain why a culturally congruent workforce has important implications for access, trust and quality of care. This wide-ranging discussion also covers: What Dr. Loarte-Rodriguez means by "narrative infrastructure" and how a book series born during COVID is now shaping workforce conversations nationwide;   The case for making mentorship a core institutional system;   Why nursing burnout is not about a lack of resiliency.  Mentioned in this episode: Latinas in NursingThe Connecticut Center for Nursing Workforce If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.  While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach.  Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development. The conversation also highlights Anocca's first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms.  This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine.  Episode Timestamps  00:00 – Introduction to TCR-T and solid tumor challenges  00:48 – Meet Reagan Jarvis and Anocca  02:05 – From New Zealand to Sweden: founder journey  03:08 – Frustration that sparked the platform  04:33 – Why CAR-T struggles in solid tumors  07:24 – The advantage of vertical integration in biotech  09:23 – First non-viral clinical trial challenges  10:56 – Umbrella trials in pancreatic cancer (KRAS focus)  14:13 – Biomarkers and building a target library  17:08 – Software, data, and machine learning in TCR discovery  18:08 – Regulatory pathways for individualized therapies  19:19 – Commercial landscape and target bottlenecks  22:29 – Expanding beyond oncology and partnerships  23:51 – Building a biotech company in Sweden  27:12 – Misconceptions about T-cell biology  30:04 – Milestones and 5-year vision  32:32 – Advice for scientific founders  34:17 – Closing thoughts  Don't forget to Like, Share, Subscribe, Rate, and Review!      Keep up with Reagan Jarvis;  LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/  Website: https://www.anocca.com/     Follow IDEA Pharma  Website: https://www.ideapharma.com/  LinkedIn: https://www.linkedin.com/company/idea-pharma/   Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

HIV research is one of the clearest examples of molecular biology in action. In this Mol Bio Minutes episode, Dr. Ryan Jeep walks through how fundamental molecular techniques power everything from detection to drug resistance studies to cure-focused research. Ryan begins with HIV biology and detection, explaining how qRT-PCR enables highly sensitive viral load measurement. These assays not only detection strategies but also support research to monitor treatment efficacy and viral rebound. From there, he moves into drug resistance, describing how sequencing, RT-PCR, and cloning strategies help researchers map resistance-associated mutations. By generating recombinant reporter viruses and measuring infectivity against different drugs, scientists can better understand treatment failure and move toward more personalized therapeutic strategies. Finally, Ryan explores cutting-edge cure research, including CRISPR-Cas9 approaches aimed at either disabling integrated viral genomes or engineering HIV-resistant immune cells. Across all three areas one theme remains constant: PCR, sequencing, and cloning form the technological backbone of HIV research. As these tools continue to evolve, so too does the potential to improve outcomes and one day eliminate the virus entirely. Since recording this episode, Ryan has joined KBI Biopharma as a Scientist l in their Formulation Development Group. Helpful resources and links: Access Stanford University's HIV Drug Resistance Database. Visit International AIDS Society's Towards an HIV Cure site, which includes resources.  Access Thermo Fisher PCR resources and products. Learn about RT-qPCR, which is relevant to HIV research.  Explore the cloning technologies referenced in this episode.  Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this episode of The Crop Science Podcast Show, Dr. Bob Stupar from the University of Minnesota explores soybean genomics, gene editing, and genomic selection in modern breeding. He explains how markers improve selection efficiency, why SCN resistance requires a multi-gene approach, and what the five-year strategic plan means for the soybean genomics community. Listen now on all major platforms!"The ability to use genomic information to predict and improve selection across entire breeding populations is growing, and even minor-effect genomic regions are becoming targets for practical breeding."Meet the guest: Dr. Bob Stupar is a Professor in the Department of Agronomy and Plant Genetics at the University of Minnesota. His research focuses on molecular genetics and genomics of legume crop species, including soybean and pea, with primary interests in the genetic basis of natural and induced phenotypic variation, developing novel genetic resources, and using genomic strategies for trait improvement.Liked this one? Don't stop now — Here's what we think you'll love!What you will learn:(00:00) Highlight(00:34) Introduction(04:20) Background(05:54) Genetics vs. genomics(10:11) Genomics in breeding(16:58) Biotechnology and GMOs(22:01) Strategic planning(27:39) Future of genomics(29:53) Final questionsThe Crop Science Podcast Show is trusted and supported by innovative companies like:- Loam Bio

Take a deep dive into gene editing, not just crispr/cas9, with Cheyenne.

The doctor is in....the box.  That's one way to describe how patients are now encountering their physicians in what's being described as the future of telehealth. Imagine that instead of a cancer patient in a rural area driving hours for an appointment to see their specialist at an academic health center, they can go to their local clinic and see a life-size, real-time, 3-D projection of them in a seven foot tall light box.  The doctor can see the patient through two-way video, and is assisted by a clinician in the exam room. The technology behind this remarkable scene is provided by a Los Angeles based start-up called Proto Hologram, whose founder and chairman, David Nussbaum, joins us on this episode of Raise the Line from Elsevier. "Our holograms start where Zoom ends and where physically being there begins," says Nussbaum, a TIME Healthcare100 honoree who has spent the last decade developing commercial and educational applications for holograms.  In addition to clinical settings, Proto units are being used at medical schools and senior living facilities and are playing a role in public health campaigns about breast cancer and vaccines. Join host Lindsey Smith for a fascinating conversation that covers: The role of holograms in extending access to specialty care; How the technology could be used to combat loneliness among seniors; Nussbaum's philosophy of "commercializing the impossible". Mentioned in this episode: Proto Hologram If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

What are the true limits of life, will we even recognize it when we see it? Neil deGrasse Tyson and comic co-host Chuck Nice explore the beginnings of life on Earth and what they might tell us about life everywhere else with astrobiologist and bacteriologist, Betül Kaçar. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free here:  https://startalkmedia.com/show/how-did-life-begin-with-betul-kacar/ Thanks to our Patrons Christian Payne, Gage Ewing, Ryan Whynot, Temirlan, 2 Lives Left, Chad Keeler, Harli Shae Smith, Brad Smith, Norm Bailey, James Peterson, Ryan Coppens, David Whittenberg, Scott Jarboe, Varun Krishnan, Eric Salinas, Mary Seman, Melissa Davis, Stephen Rockwell, Catrina, Max Wilburn, Keith Koenigsberg, LEIII, Vincent Loniello, Simon Toth, DoctorWaterGod, Ruthanne Nava, Martineau Alex, Matthew, Phil, Jaden, Arik Drori, Papersneaker, Steven Peeters, Trey Durango, Julianne, Robbie James, Jason Foreman, Liam, Steven Van Vleet, Marilyn, Zakk Why, Ben Wheeldon, Erik Leazure, Konal Sharma, Dušan Živanović, Erik Strandberg, Berklie Novak-Stolz, Kazi Mahin Mahfuz, Tim Van Devender, Andrew Martin, Jason F, Charles Joubert, Youcef Kazwiny, Joy Joslyn, Freeman, Jessica, Pat, Phillip Brooks, Michael Hues, Jacqueline Sinclair, Robert Marsh, Botas, Raza Naqvi (Sid), Jake, Christine Bartholomew & Family, Mr Xoot, Dyonté Houston, Daryl, Rob Weiss, Caleb Holmes, Jeffrey Luce, Kellie Owczarczak, Brandt Reppond, Joseph Savage, Grace Smith, Joe Pacillo, Gregory Wright, Eric Brothwell, IvanM, Pattie Particle, Cory Fenstermaker, James H Lawson, Embreebane, Dai Stiho, Raymond C King, J M, Alex Wheeler, Jason Rushmore, Idris, Damian Correa, Dylan Woody, Julia Nolen, Chris Petit, Anna, David Kapner, Lalo, Vic, Ash Anthony, and Wayne Stubblefield for supporting us this week. Subscribe to SiriusXM Podcasts+ to listen to new episodes of StarTalk Radio ad-free and a whole week early.Start a free trial now on Apple Podcasts or by visiting siriusxm.com/podcastsplus. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“One of the reasons The Pitt has been so successful is because it's showing real expertise in a time when everybody thinks they're an expert,” says Dr. Mel Herbert, who brings decades of experience as an emergency medicine specialist to his work as a writer and consultant on the hit HBO Max show. Dr. Herbert, who was also a consultant on the groundbreaking TV drama ER, is one of seven physicians on The Pitt's writing and production team, which explains the high degree of medical accuracy that is a hallmark of the show. But Dr. Herbert is also proud of the emotional accuracy captured on screen. “It's about the emotions. It's about the stress. It's about how it really affects the doctors and the nurses that I've found the most interesting to write about.” In this candid conversation with host Lindsey Smith, Dr. Herbert talks about his own struggles coping with the demands of life in the emergency room and the importance of letting clinicians know that help is available. “You don't have to suffer. We can help you now in ways we couldn't even do ten years ago. That's the story I want to tell.”  In addition to his work using TV as an educational vehicle, Lindsey and Dr. Herbert discuss his real world efforts to provide emergency medicine education across the globe through his companies EM:RAP and EM:RAP GO.  Stay tuned to this very special episode of Raise the Line with Elsevier in which you will also: Learn how writers tackle misinformation and hot button health topics; Get a behind the scenes look at how actors learn complex medical terminology; Discover who Dr. Herbert's favorite characters are. Mentioned in this episode: The PittMental Health Resources from American College of Emergency PhysiciansEM:RAPThe Extraordinary Power of Being Average If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

I bust through the third wall or whatevs in Episode 10 of TSC Talks 3.0 Research. Dropped the whiteboard til the end. Summed up the 9 episodes and added a bit on the end about CPTSD, TAND and the fact that the entire family system is drawn into the grid as data churnin' emotin' node. Used the Google AI to investigate the theories I had on amplification of TSC by multiple factors for purpose and product and it proved true based on the research plus lived experience thus far.Source Links for Further ResearchI. Rare Disease Advocacy and Funding (Conflicts of Interest)[TSC Alliance: Corporate Policies](https://www.tscalliance.org/about-tsc/corporate-policies/)[TSC Alliance: COVID-19 Vaccine Position Statement](https://www.tscalliance.org/wp-content/uploads/2021/08/TSC-Alliance-COVID-19-Vaccine-Position-Statement-Update-August-2021-FINAL.pdf)[TSC Alliance: Phenotypic Variability Research](https://www.tscalliance.org/tsc-matters/phenotypic-variability-in-tuberous-sclerosis-complex-tsc/)[TSC Alliance: 2024 Talking Points](https://www.tscalliance.org/wp-content/uploads/2024/01/2024-Talking-Points-Final.pdf)[NORD: Mission and Values](https://rarediseases.org/about-us/mission-values/)[NORD: Research Grant Programs](https://rarediseases.org/advancing-research/research-grant-programs/) [EURORDIS: Our Funding](https://www.eurordis.org/who-we-are/our-funding/)[Mass General: Herscot $50 Million Gift](https://giving.massgeneral.org/stories/herscots-make-50-million-gift-to-mass-general)[NEJM: Industry Support for Patient Advocacy](https://www.nejm.org/doi/full/10.1056/NEJMsr1610625)II. Gene Therapy (CRISPR), Risks, and Regulation [FDA: Cellular & Gene Therapy Products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products)[CRISPR-Cas9 Off-Target Effects (Synthego)](https://www.synthego.com/blog/crispr-off-target-editing/)[CRISPR: Genome Engineering Advantages and Limitations (Taconic)](https://www.taconic.com/resources/crispr-genome-engineering-advantages-limitations)[FDA: Regulatory Distinctions for Cell and Gene Therapies (LinkedIn)](https://www.linkedin.com/pulse/fda-vs-ema-key-regulatory-distinctions-cell-gene-therapies-ywzye) [Informed Consent and Clinical Trials (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2659702/) [Immune Evasion in Engineered CRISPR Enzymes (Broad Institute)](https://www.broadinstitute.org/news/scientists-engineer-crispr-enzymes-evade-immune-system) [The Ethics of Gene Editing (Innovative Genomics)](https://innovativegenomics.org/crisprpedia/crispr-ethics/)III. Vaccines, Toxins, and Environmental Amplification [TSC Drug Market & Prevalence (OpenPR)](https://www.openpr.com/news/3536609/tuberous-sclerosis-complex-drug-market-2034-epidemiology)[Vaccines and the Rise in Pediatric Cancer (The Vaccine Reaction)](https://thevaccinereaction.org/2018/05/is-there-a-link-between-vaccines-and-the-rise-in-pediatric-cancer/) [Study of Vaccinated and Unvaccinated Children (Weston A. Price)](https://www.westonaprice.org/health-topics/vaccinations/chronic-disease-a-study-of-vaccinated-and-unvaccinated-children/#gsc.tab=0)[Role of Environmental Toxins in Epigenetic Dysregulation (PLM Institute)](https://plminstitute.org/plmi-blog/the-role-of-environmental-toxins-in-epigenetic-dysregulation/) [Childhood Vaccination Schedule Explosion (Twitter - NVICLoeDown)](https://twitter.com/NVICLoeDown/status/1687176816774033408) [COVID-19 Vaccine Added to Childhood Schedule (Children's Health Defense)](https://childrenshealthdefense.org/defender/childhood-covid-vaccine-schedule/) [The Role of Environmental Exposures in Genetic Disease (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4021822/)IV. Alternative and Holistic Approaches[Ketogenic Diet Inhibits the mTOR Pathway (AESnet)](https://aesnet.org/abstractslisting/the-ketogenic-diet-inhibits-the-mammalian-target-of-rapamycin-(mtor)-pathway)[Ketogenic Diet for Epilepsy in TSC (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5540690/) [Curcumin Inhibits mTOR Activity (ScienceDirect)](https://www.sciencedirect.com/science/article/abs/pii/S0944711318304860)[Natural Treatment for TSC (Inspire Forum)](https://www.inspire.com/groups/tuberous-sclerosis-complex/discussion/natural-treatment-for-tsc/)[Natural Products and Patenting (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521639/) [Anti-Inflammatory Living (Holistic Health Code)](https://www.holistichealthcode.com/articles/unlocking-metabolic-health)contact Jill: pjlacy6@gmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Your doctor tells you that, should you wish to have a child, that child is likely also to carry the disease. But a new gene-editing technology could ensure that your baby is -- and remains -- healthy. Should you do it? Critics say the technology will exacerbate inequality and meddle in the most basic aspect of our humanity. Now, we debate: Should We Use Gene Editing to Make Better Babies? This ethical conundrum is at the crux of this week's debate, originally broadcast in February 2022. Arguing Yes: Dr. George Church, Geneticist & Founder, Personal Genome Project; Professor, Genetics, Wyss Institute and Harvard Medical School Amy Webb, Chief Executive Officer, Future Today Strategy Group; Professor, NYU Stern School of Business  Arguing No: Marcy Darnovsky, Executive Director, Emerita, Center for Genetics and Society  Françoise Baylis, Distinguished Research Professor, Emerita, Dalhousie University; President, Royal Society of Canada  Emmy award-winning journalist John Donvan moderates  Join the conversation on Substack - share your perspective on this episode and subscribe to our weekly newsletter for curated insights from our debaters, moderators, and staff.  Follow us on YouTube, Instagram, LinkedIn, X, Facebook, and TikTok to stay connected with our mission and ongoing debates.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

"Headache is just a teeny piece of the puzzle," says Dr. Regina Krel, an insight that's at the heart of why migraine syndrome, one of the leading causes of disability worldwide, remains so persistently misunderstood. In this informative conversation with Raise the Line from Elsevier host Michael Carrese, Dr. Krel, the director of Headache Medicine at Hackensack University Medical Center, explains migraine as a storm that sensitizes the entire brain, not just the site of the headache, which explains the long list of symptoms people experience including sensitivity to light and sound, brain fog, fatigue and problems with balance. “The headaches can be severe, but it's the other symptoms that really kind of take over your whole body that make patients dysfunctional.” Dr. Krel also explains why migraine disproportionately impacts women in the prime of their working and caregiving years, and offers guidance for treating migraines in women, whose symptoms are commonly dismissed by non-specialists. Stay tuned to also learn about: The "migraine triangle"; Why stigma around migraine persists even in doctors' offices; New treatment options including neuromodulation devices. Mentioned in this episode: Headache Center at Hackensack University Medical Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In this episode of Biotech Breakthroughs, Matt Phipps, group head of biotech research, speaks with William Blair biotech analyst Myles Minter about how gene editing is moving from early hype toward clinically validated therapies. They discuss lessons from the first approved ex vivo product and highlight key 2026 catalysts across CRISPR, base editing, RNA editing, and DNA writing.

******Support the channel******Patreon: https://www.patreon.com/thedissenterPayPal: paypal.me/thedissenterPayPal Subscription 1 Dollar: https://tinyurl.com/yb3acuuyPayPal Subscription 3 Dollars: https://tinyurl.com/ybn6bg9lPayPal Subscription 5 Dollars: https://tinyurl.com/ycmr9gpzPayPal Subscription 10 Dollars: https://tinyurl.com/y9r3fc9mPayPal Subscription 20 Dollars: https://tinyurl.com/y95uvkao ******Follow me on******Website: https://www.thedissenter.net/The Dissenter Goodreads list: https://shorturl.at/7BMoBFacebook: https://www.facebook.com/thedissenteryt/Twitter: https://x.com/TheDissenterYT This show is sponsored by Enlites, Learning & Development done differently. Check the website here: http://enlites.com/ Dr. Jeff McMahan is Sekyra and White's Professor of Moral Philosophy at the University of Oxford. He specializes in Practical Ethics, Political Philosophy, and Ethics. He is editor of the Journal of Controversial Ideas. He's the author of books like The Morality of Nationalism, The Ethics of Killing: Problems at the Margins of Life, and Killing in War. In this episode, we talk about reproductive ethics. We first discuss antinatalism, and what makes life worth living or starting. We explore the ethics of abortion. We talk about extinctionism. We discuss the ethics of gene editing and embryo selection, and eugenics. Finally, we talk about population ethics, and explore questions such as whether there are instances where there would be a duty to reproduce; whether women are coerced into reproducing; and overpopulation, and instances where there would be a moral duty to not reproduce.--A HUGE THANK YOU TO MY PATRONS/SUPPORTERS: PER HELGE LARSEN, BERNARDO SEIXAS, ADAM KESSEL, MATTHEW WHITINGBIRD, ARNAUD WOLFF, TIM HOLLOSY, HENRIK AHLENIUS, ROBERT WINDHAGER, RUI INACIO, ZOOP, MARCO NEVES, COLIN HOLBROOK, PHIL KAVANAGH, SAMUEL ANDREEFF, FRANCIS FORDE, TIAGO NUNES, FERGAL CUSSEN, HAL HERZOG, NUNO MACHADO, JONATHAN LEIBRANT, JOÃO LINHARES, STANTON T, SAMUEL CORREA, ERIK HAINES, MARK SMITH, JOÃO EIRA, TOM HUMMEL, SARDUS FRANCE, DAVID SLOAN WILSON, YACILA DEZA-ARAUJO, ROMAIN ROCH, YANICK PUNTER, CHARLOTTE BLEASE, NICOLE BARBARO, PAWEL OSTASZEWSKI, NELLEKE BAK, GUY MADISON, GARY G HELLMANN, SAIMA AFZAL, ADRIAN JAEGGI, JOÃO BARBOSA, JULIAN PRICE, HEDIN BRØNNER, FRANCA BORTOLOTTI, GABRIEL PONS CORTÈS, URSULA LITZCKE, SCOTT, ZACHARY FISH, TIM DUFFY, SUNNY SMITH, JON WISMAN, WILLIAM BUCKNER, LUKE GLOWACKI, GEORGIOS THEOPHANOUS, CHRIS WILLIAMSON, PETER WOLOSZYN, DAVID WILLIAMS, DIOGO COSTA, ALEX CHAU, CORALIE CHEVALLIER, BANGALORE ATHEISTS, LARRY D. LEE JR., OLD HERRINGBONE, DAN SPERBER, ROBERT GRESSIS, JEFF MCMAHAN, JAKE ZUEHL, MARK CAMPBELL, TOMAS DAUBNER, LUKE NISSEN, KIMBERLY JOHNSON, JESSICA NOWICKI, LINDA BRANDIN, VALENTIN STEINMANN, ALEXANDER HUBBARD, BR, JONAS HERTNER, URSULA GOODENOUGH, DAVID PINSOF, SEAN NELSON, MIKE LAVIGNE, JOS KNECHT, LUCY, MANVIR SINGH, PETRA WEIMANN, CAROLA FEEST, MAURO JÚNIOR, TONY BARRETT, NIKOLAI VISHNEVSKY, STEVEN GANGESTAD, TED FARRIS, HUGO B., JORDAN MANSFIELD, CHARLOTTE ALLEN, PETER STOYKO, DAVID TONNER, LEE BECK, PATRICK DALTON-HOLMES, NICK KRASNEY, RACHEL ZAK, DENNIS XAVIER, CHINMAYA BHAT, RHYS, ALEX MACLEOD, HAIDAR, JULIEN PORCHER, ROBERT SUNDSTRÖM, AND JON STEWART!A SPECIAL THANKS TO MY PRODUCERS, YZAR WEHBE, JIM FRANK, ŁUKASZ STAFINIAK, TOM VANEGDOM, BERNARD HUGUENEY, CURTIS DIXON, THOMAS TRUMBLE, KATHRINE AND PATRICK TOBIN, JONCARLO MONTENEGRO, NICK GOLDEN, CHRISTINE GLASS, IGOR NIKIFOROVSKI, PER KRAULIS, ADAM HUNT, AND ANTHONY DI LORENZO!AND TO MY EXECUTIVE PRODUCERS, MATTHEW LAVENDER,SERGIU CODREANU, AND GREGORY HASTINGS!

To mark the sixth anniversary of Raise the Line from Elsevier we're revisiting one of the most remarkable stories we've had the privilege of sharing over the last 575 episodes. To do that, we're delighted to welcome back Dr. David Fajgenbaum, a physician-scientist who repurposed an existing medication that saved his own life from Castleman disease, an ultra-rare condition that nearly killed him on five occasions. Because there was no treatment specifically for Castleman, Dr. Fajgenbaum set out to find a previously approved medication that might work. “I eventually found a drug that was made for another disease 50 years ago. It's been over 12 years that I've been doing great on this medicine.”   When he first joined us in 2022, Dr. Fajgenbaum was just launching a non-profit organization called Every Cure with the hope of replicating the success he achieved in his own case, and as you'll learn in this inspiring interview with host Lindsey Smith, its work has already saved thousands of lives. “It's a tragedy if someone dies while there's already a drug in their local hospital that could help them.”  In the latest installment of our Year of the Zebra series on rare conditions, you'll hear an inspiring example of a life saved by this approach and also learn about: The role of artificial intelligence in scanning thousands of medications and diseases to find possible matches; How Every Cure decides which drugs merit the costly research needed to confirm a match;  Dr. Fajgenbaum's philosophy of “living in overtime.” Mentioned in this episode:Every Cure Osmosis Video on Castleman Disease Dr. Fajgenbaum's Bestselling Memoir, Chasing My Cure If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Episode 8 of TSC Talks 3.0 Research... continuing on with the extensive history of the rare disease Tuberous Sclerosis Complex, the set up for data harvesting and gene editing and the inevitability of enhanced grid adhesion. Woohoo! Next episode I'm gonna go into mitigation and the upswing of the sitch. Links:mindandbodyexercises.comhttps://medium.comhttps://maescenter.comrockarch.orgtikvahhealthandwellness.comnih.govnih.govnutritiondiagnostics.com.aunih.govpsychologytoday.comnih.govmcgill.cachop.eduhttps://historyofvaccines.orgnih.govjpeds.comhttps://time.comnih.govnih.govnih.gov2minutemedicine.comnih.govnih.govsciencedirect.comnih.govcdc.govnih.govhttps://richd.orgnih.govwikipedia.orgempr.comhttps://historyofvaccines.orghttps://drgreenmom.commayoclinic.orgkaiserpermanente.orgnih.govkff.orgforbes.comitu.intciocoverage.comhttps://studyfinds.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

How AI Could Strengthen the Doctor-Patient Relationship: Dr. Ashwin Vasan, Senior Fellow in Health Policy and Global Affairs at Yale School of Public Health and Affiliate Faculty at Yale Jackson School of Global Affairs “Ultimately, AI needs to be a tool that doesn't break down trust or empathy or clinical judgment, but rather helps enhance those things.” That aspirational perspective from Dr. Ashwin Vasan, Senior Fellow in Health Policy and Global Affairs at the Yale School of Public Health and Affiliate Faculty at the Yale Jackson School of Global Affairs, frames a nuanced conversation about one of healthcare's most consequential changes. Drawing on his experience as New York City Health Commissioner during the COVID-19 crisis and decades in global and public health, Dr. Vasan argues that the future of AI in medicine should be shaped less by the technology itself than by the values guiding its implementation, and that physicians need to play an active role in this process. “I think it behooves us to engage with this technology and steer it in the directions that we want as a society.” This timely discussion also offers Dr. Vasan's thoughtful perspectives on: How AI could allow physicians to focus on the human side of care; The risks of AI reinforcing inequities and driving costs higher; Public health as the marriage of science, society and trust. Join host Lindsey Smith for a valuable Raise the Line episode on how AI can be harnessed to benefit patients and provides alike.  Mentioned in this episode: Yale School of Public Health Yale Jackson School of Public Affairs If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

The history of Tuberous Sclerosis Complex.they're juicing it.Some queries related to the complexity of epigenetic variables and the overlords decision to focus on genetics only for the sake of "simplicity"...Just my opinion?I welcome all listeners and critical thinkers.

Imagine you had a tutor who was with you every time you were studying and, because they knew your learning style, strengths and weaknesses, could hand you the right content at the moment you needed it to deepen your understanding of a topic.  That's the pedagogically powerful experience students are having with AI-enhanced learning systems such as Osmosis AI, making possible what our guest, Elsevier's Chief AI Officer Paul Crockett, describes as a new era of precision learning.  “We now have signal from how students actually engage with content – such as where they get stuck and how they learn – and that behavioral data can tell you more about what a learner needs than any sort of static assessment. That's a profound transformation,” he says. In this fascinating conversation with Raise the Line host Lindsey Smith, Crockett also highlights how AI enables tutoring-like interactions with students which supports deeper reasoning rather than rote memorization. That in turn, helps Elsevier achieve the goal of getting students ready to practice medicine, not just ready to take tests. In addition, limiting the AI's sources to the evidence-based material in the Osmosis and Elsevier content libraries provides both students and faculty with the level of trust and verifiability they desire. Tune in to learn how this meaningful shift from static content delivery to dynamic, data-informed learning experiences is changing healthcare education. Mentioned in this episode: Osmosis AI If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In Episode 6 of TSC Talks Research 3.0, I finish up the discussion of CRISPR and TSC and the trajectory, I get into cannabis and the way they've deglimmered exploration of consciousness for those with rare diseases on hefty meds and how this relates to the cultivated biosphere that limits the full potential of the divine human. So many the templates for data and experimentation to build the current Healthcare 4.0 system and Precision Medicine. While many will be helped, there will be a dependence on the grid system.YouTube Video: https://youtu.be/OqLKIZ7Q54s?si=8svWmKHp4ekiFOnRLinks: https://www.liebertpub.com/doi/10.1089/crispr.2024.0079 https://pubmed.ncbi.nlm.nih.gov/39654514/ https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7793581/ https://innovativegenomics.org/news/crispr-clinical-trials-2026/ https://frontlinegenomics.com/sickle-cell-disease-a-2024-update/ epidiolexhcp.com nih.gov sciencedaily.com https://www.researchgate.net/publication/348347376_Gene_therapy_for_tuberous_sclerosis_complex_type_2_in_a_mouse_model_by_delivery_of_AAV9_encoding_a_condensed_form_of_tuberin globalgenes.org neurologylive.com berkeley.edu ccf.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Tim and Tyler talk with Ian Miller about the latest in the plant gene editing sector, including recent funding rounds, new traits, and more. — This episode is presented by Yield Energy. Yield for Growers. — Links Pairwise - https://www.pairwise.com  Farmer Mode Hats - https://farmermode.com 

Send us Fan MailDr. Michael Koren joins Kevin Geddings to discuss how clinical research leaves patients with clarity, support and new care options, including through new gene editing studies for high cholesterol. They then move to talking about studies involving GLP-1 weight loss drugs and investigations into how to improve them.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In this episode I share information on the risks and side effects of CRISPR for individuals with TSC and in general as well as go into how those affected with TSC are "test bunnies" for much of this new technology, and my theories with documentation of why this is happening. I also go over some of the "no touch" technologies being rolled out and tested on those with diseases such as TSC where the nature of the genetics, a "monogenic" disorder, makes it a more suitable population to experiment on to gain information than other more common disorders, such as Alzheimer's, which involve 100s of genetic factors.  TSC population is kept in that "test bunny" role without ever addressing the external factors that make the disease more difficult to manage in the first place.LINKS:pmc.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/https://cdmrp.health.mil/tscrp/defaulthttp://tuberous-sclerosis.org/research/tsa-funded-research/https://www.mdpi.com/2075-1729/15/3/368https://www.tscalliance.org/wp-content/uploads/2023/02/Training-Packet-Documents.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC3010088/https://pmc.ncbi.nlm.nih.gov/articles/PMC4527140/https://pubmed.ncbi.nlm.nih.gov/19028034/https://pmc.ncbi.nlm.nih.gov/articles/PMC6851053/https://www.youtube.com/watch?v=hXRRq-dFuYghttps://www.youtube.com/watch?v=Hu2TvhhdEHYhttps://www.youtube.com/watch?v=BFuXttZspaYhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5727703/https://globalgenes.org/raredaily/transforming-tsc-epilepsy-with-a-precision-therapy/https://pediatricsnationwide.org/2024/01/11/innovative-gene-therapy-approach-for-treating-patients-with-tuberous-sclerosis-type-2/https://pmc.ncbi.nlm.nih.gov/articles/PMC3164024/https://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/https://www.biorxiv.org/content/10.1101/2024.02.22.581652v1.full-texthttps://pmc.ncbi.nlm.nih.gov/articles/PMC6408922/https://www.mdpi.com/2076-3417/14/3/1132https://pmc.ncbi.nlm.nih.gov/articles/PMC3744999/https://www.researchgate.net/publication/24217930_Magnetically_Responsive_Nanoparticles_for_Drug_Delivery_Applications_Using_Low_Magnetic_Field_Strengthshttps://pmc.ncbi.nlm.nih.gov/articles/PMC2933363/https://pmc.ncbi.nlm.nih.gov/articles/PMC7998448/https://pmc.ncbi.nlm.nih.gov/articles/PMC9230665/Become a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

Send us Fan MailDr. Michael Koren joins Kevin Geddings to discuss a new concept in cholesterol treatment: gene editing. Dr. Koren talks about a new study, just opening in the United States, that is the first of its class. This study explores gene editing to tackle familial hypercholesterolemia (high cholesterol caused by genetics) through a once-in-a-lifetime, single-shot treatment.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

“Every person deserves kindness, dignity, and respect, regardless of what their medical situation is,” says Madison Donnelly, PA-C, who joins host Dr. Parsa Mohri on the latest installment of our NextGen Journeys series. As you'll hear in this thoughtful conversation, Madison is bringing that commitment to patient advocacy and equitable care to her patients at Community Care Physicians in Albany, New York. A graduate of Hofstra University's PA program, Madison describes how the profession's flexibility and team-based approach enables clinicians to expand access to care, particularly in high-demand specialties like women's health and primary care. Drawing on her work in obstetrics and gynecology, she highlights persistent gaps in women's health, including America's troubling maternal mortality rates and the long delays many patients face in receiving diagnoses for endometriosis and other conditions. “There's a difference between telling someone something and being heard,” she notes, emphasizing that women's symptoms are still too often dismissed in clinical settings. The episode also explores overlooked populations -- including NICU families and patients with eating disorders -- where stigma, mental health challenges, and fragmented follow-up care can leave people vulnerable long after the initial medical crisis. Don't miss this Raise the Line dialogue about the evolving role of physician associates and how early-career clinicians can help build a more humane and responsive system. Mentioned in this episode: Community Care Physicians Hofstra University Physician Assistant Program If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

TSC Talks 3.0 Research, Episode 4Here's my ongoing convo with AI delving into the funding behind rare disease research, non profits and how there are vested interests in continuing to bypass the full range of knowledge about what impacts the genome such as environmental (vaccines included) amplifications so they can justify the need for gene therapy via crispr, etchttps://rarediseases.org/about-us/financials-governance/https://rarediseases.org/collection/nord-financials/https://rarediseases.org/nord-releases-report-on-the-state-of-rare-disease-diagnosis-care-and-treatment-in-america-over-three-decades/https://rarediseases.org/nord-state-report-card/rarediseases.orghttps://rarediseases.org/wp-content/uploads/2022/10/NORD_2020_Annual-Report_wFinancials.pdfhttps://rarediseases.org/wp-content/uploads/2022/01/NORD_2020_Annual-Report_FINAL_SpreadView_web.pdfhttps://rarediseases.org/wp-content/uploads/2022/10/NRD-1198-2019_Annual-Report_FNL_WebSize.pdfhttps://www.eurordis.org/who-we-are/our-funding/https://www.eurordis.org/who-we-are/projects-and-partnerships/https://www.eurordis.org/partnerships/https://www.eurordis.org/get-involved/join-the-eurordis-round-table-of-companies/https://www.eurordis.org/publications/eurordis-policy-on-financial-support-by-commercial-companies-2/https://www.eurordis.org/our-priorities/research/https://www.eurordis.org/eurordis-supports-member-states-efforts-operating-grants-reintroduction/https://www.eurordis.org/videos/rare-but-real-talking-rare-diseases-part-1-6/download2.eurordis.orgvzacna-onemocneni.czhttps://everylifefoundation.org/rare-hub/rare-hub-partners-current-1-3/https://everylifefoundation.org/financial-support/https://everylifefoundation.org/everylifeeveryaction/https://everylifefoundation.org/sitemap/https://everylifefoundation.org/wp-content/uploads/2025/08/ELF-AnnualReport-2024-8.5x11-Proof-v6-081225.pdfhttps://everylifefoundation.org/wp-content/uploads/2022/01/Guide-to-Patient-Involvement-FINAL-COMPLETE-GUIDE-Rev.pdfhttps://everylifefoundation.org/wp-content/uploads/2016/05/Industry-Brochure-FINAL-May-2016.pdfBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.

We've spoken with many guests about clinical and technological trends impacting healthcare providers, but less so about the trends on the business side of practicing medicine.  So on this episode, we're going to make up for that by spending our time with Dr. Alexander Vaccaro, an influential spine surgeon and president of one of the largest musculoskeletal practices in the U.S. -- Rothman Orthopaedic Institute -- which treats patients at over 40 locations in Pennsylvania, New Jersey, New York and Florida. While Dr. Vaccaro understands the desire for financial stability that's increasingly driving young physicians into the arms of hospital systems, he worries about what's being lost with the resulting decline in the number of independent practices.  “If you didn't have private practice advocating for the doctor, the insurance companies would bully the healthcare profession.” Join Raise the Line host Michael Carrese for a candid and lively conversation that also covers: How physician autonomy and entrepreneurship can drive innovation; The economic and policy forces reshaping private practice medicine; The role of research partnerships between private practices and universities. Mentioned in this episode:Rothman Orthopaedics If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

We've had many conversations on Raise the Line about the challenges of health communication in today's world of information overload, but none of our guests have the kind of expertise Dr. Tesfa Alexander has acquired in a career that has taken him from Madison Avenue to the halls of government and academia. From guiding tobacco education research at the FDA to leading public health initiatives at MITRE, Dr. Alexander has developed a deep understanding of the science and strategy behind effective health communication. “Successful campaigns keep the long game in mind where you want to develop a lasting relationship with your target audience,” he tells host Lindsey Smith. That relationship needs to be built on understanding culture, beliefs, priorities and daily realities, and only then can you develop messaging that will resonate, he explains. Dr. Alexander also believes these relationships can be leveraged to help people sort out facts from misleading or inaccurate claims. “I strongly recommend shifting our focus from combating misinformation head on, and instead working with the communities who we are seeking to serve.” This fascinating look at communication science also covers: How stories drive belief; The importance of working with community partners who are trusted messengers;  The power of audience segmentation. Tune in as Dr. Alexander unpacks what it takes to influence beliefs, and ultimately behaviors, in an era defined by misinformation and institutional mistrust. Mentioned in this episode:Lerner Center for Public Health Advocacy If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

On today's episode, Andy travels to Austin to visit with Ways2Well founder Brigham Buhler at his Longevity Lab lab to discuss the search for the genetics secrets to eliminating chronic disease and how some species seem to live forever. They dig into why how the field is practiced today often leave patients without real answers, and why Buhler believes a more preventative, patient-focused approach could change that. Change Agents is an IRONCLAD Original Chapters: (00:00) Intro (02:08) Redesigning the Clinic: Making Healthcare Fun (07:10) How Insurance & PBMs Broke the Medical System (14:42) Big Pharma's War on Compounding & Telemedicine (18:22) Why Your Doctor Is Trapped in a Broken System (21:18) Ways2Well Tour: 80s Nostalgia & UV Murals (30:52) The Opioid Crisis & Brigham's Origin Story (38:25) Fighting the FDA & The Illusion of Surgical Safety (43:47) What Are Peptides & Why Pharma Wants Them (48:22) ALLEN: The Ways2Well AI Health Assistant (52:14) Debunking Medical Myths: Testosterone & HRT (58:16) Wearables & The Future of Proactive Health (01:10:57) Inside the Lab: Stem Cells, Red Light, & Hyperbaric Oxygen (01:17:48) Next-Level Detox: Blood Filtration (IBU) & Ozone Saunas (01:20:25) Gene Editing & The Future of Human Evolution Sponsors: Firecracker Farm Use code IRONCLAD to get 15% off your first order at https://firecracker.farm/ GHOSTBED: Go to https://www.GhostBed.com/IRONCLAD and use code IRONCLAD for an extra 15% off sitewide. Subscribe on Apple Podcasts: https://podcasts.apple.com/us/podcast/change-agents-with-andy-stumpf/id1677415740 Subscribe on Spotify: https://open.spotify.com/show/3SKmtN55V2AGbzHDo34DHI?si=5aefbba9abc844ed Learn more about your ad choices. Visit megaphone.fm/adchoices

Host Casey Harper is joined by Dr. David Prentice, who is one of the founders for Science Alliance For Life and Technology (SALT) and The Washington Stand’s Jared Bridges to discuss the current ethical concerns surrounding lab-created embryos. David shares why he started SALT, the development and dangers of gene screening and modification, and the role AI is currently playing in embryo selection.

Pairwise: https://www.pairwise.com/FoA 412: 'Biological' Is Not A Category (it's the future of agriculture)I'm excited to share today's episode with you. I've wanted to get Tom Adams back on the show ever since I had the chance to interview him at World Agritech a couple of years ago. That interview was included on episode 412 of this podcast titled “Biological is not a Category”. The work Pairwise is doing is mind boggling to me. Using CRISPR and the latest in gene editing tools, they have built a platform to enable plant breeders to make very precise changes to the genome of a plant to give farmers and consumers more of what they want. Now this is different from genetic modification or GMOs because they are not inserting foreign genes into the plant. In fact, they are doing the exact same thing that plant breeders have done for over a century, they are just able to do it in an extremely precise way. On another podcast that I host, Agriscience Explained, Corteva's Reza Rasoulpour explained natural breeding as wanting to change one word in a book by just combining all of the pages of two different books and hoping that word changes. Versus gene editing just going in and changing that one word in the book. I thought that was a good comparison. So Tom and his team are bringing this technology to agriculture by working with seed companies and other partners in a variety of use cases, many of which we'll discuss today. A little background on Tom: Dr. Tom Adams co-founded Pairwise and serves as Chief Executive Officer. Tom has over 25 years of leadership experience heading up biotechnology for global companies, serving most recently as Vice President of Global Biotechnology at Monsanto where he led the team developing a broad range of innovative products. Tom wanted to realize the possibilities of CRISPR and gene editing in plants, and co-founded Pairwise to realize this potential in a mission-based environment. Formerly a faculty member at Texas A&M University, Tom holds a PhD in microbiology and plant science from Michigan State University and a BS in botany and plant pathology from Oregon State University. Tom and I talk about Pairwise's continued work in this area, some of the cool developments that are under way, some of their strategic decisions like going the partnership route rather than being the seed company themselves, a little bit more about how the technology works, how this changes the game and who captures the value.

Patrick Bet-David and Rhonda Patrick explore AI's explosive rise, gene therapy, CRISPR, stem cell reprogramming, and longevity breakthroughs. They debate designer genetics, IQ enhancement, organ regeneration, and whether the future belongs to superhumans or authentic human imperfection.

When it comes to “bad” cholesterol, most cardiologists say lower is better. But what's the best way to get that number down? Can diet and exercise alone do the job?Cardiologists Kiran Musunuru and Neha Pagidipati join Host Ira Flatow for a look at the latest in cholesterol-lowering treatments, including CRISPR technology that could turn off cholesterol-making genes for life. How does it work, and is it safe?Guests:Dr. Kiran Musunuru is the scientific director of the Center for Inherited Cardiovascular Disease at the Perelman School of Medicine at the University of Pennsylvania.Dr. Neha Pagidipati is the director of the Cardiometabolic Prevention Clinic at the Duke University School of Medicine in Durham, NC.Transcripts for each episode are available within 1-3 days at sciencefriday.com.  Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.